Ress Life Investments A/S
28.1.2021 11:45:52 CET | Globenewswire | Press release
Ress Life Investments A/S
Holbergsgade 14, 2 tv
DK-1057 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 28 January 2021
Corporate Announcement 3/2021
Ress Life Investments A/S announces capital increase.
The Board of Directors in Ress Life Investments A/S has today resolved to utilise its authorisation in article 4.8 of the articles of association to increase the company's share capital with nominally EUR 1,324,000 by issuance of 2,648 new shares with a nominal value of EUR 500 each at a price of EUR 1,711.42 per share of EUR 500 without pre-emption rights for the company's existing shareholders.
After the capital increase, the registered share capital of the company is EUR 57,976,000 divided into 115,952 shares of EUR 500 nominal value each. Each share of nominal EUR 500 carries one vote at general meetings in Ress Life Investments A/S.
The new shares will be admitted for trading and official listing on NASDAQ Copenhagen A/S under the same ISIN code as the company's existing shares.
Updated articles of association of the company are attached.
Questions related to this announcement can be made to the company’s AIF-manager, Resscapital AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@resscapital.com
Tel +46 7 366 072 42
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
